4:51 PM
 | 
Jan 27, 2014
 |  BC Extra  |  Top Story

Pfizer's dacomitinib misses in NSCLC trials

Pfizer Inc. (NYSE:PFE) reported data on Monday from two double-blind, international Phase III trials evaluating once-daily oral dacomitinib ( PF-00299804) to treat advanced non-small cell lung cancer (NSCLC). In the ARCHER 1009 trial, dacomitinib missed the co-primary endpoints of improving progression-free survival (PFS) vs. Tarceva erlotinib in all NSCLC patients...

Read the full 242 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >